Message #38 From:
NewsBot Date: November 2, 2006 08:28:00 AM
CYKN News Cyberkinetics Neurotechnology Systems, Inc. Announces Third Quarter 2006 Earnings Conference Call
FOXBOROUGH, Mass.--(BUSINESS WIRE)--Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN) (“Cyberkinetics”),
a leader in the neurotechnology industry, will hold its quarterly
conference call to discuss third quarter results on Wednesday, November
8, 2006, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time).
Those who would like to participate in the conference call should dial
800-591-6942, or 617-614-4909 for international participants, and use
the pass code 20398844. To access a replay of the conference call, which
will be available from 12:30 p.m. Eastern Time on November 8 until 5:00
p.m. Eastern Time on November 15, please dial 888-286-8010, or
617-801-6888 for international callers, and use the pass code 62331640.
An audio webcast of the conference call will also be available at www.cyberkineticsinc.com
on Cyberkinetics’ investor relations page. The
webcast is also being distributed through the Thomson StreetEvents
Network. Individual investors can listen to the call at www.earnings.com,
Thomson’s individual investor portal, powered
by StreetEvents. Institutional investors can access the call via www.streetevents.com,
a password-protected event management site.
About Cyberkinetics Neurotechnology Systems, Inc.
Cyberkinetics Neurotechnology Systems, Inc., a leader in the
neurotechnology industry, is developing neural stimulation, sensing and
processing technology to improve the lives of those with severe
paralysis resulting from spinal cord injuries, neurological disorders
and other conditions of the nervous system. Cyberkinetics’
product development pipeline includes: the Andara™
Oscillating Field Stimulator (OFS™) Device, an
investigative device designed to stimulate regeneration of the neural
tissue surrounding the spinal cord; the BrainGate System, an
investigative device designed to provide communication and control of a
computer, assistive devices, and, ultimately, limb movement; and the
NeuroPort™ System, a neural monitor designed
for acute inpatient applications and labeled for temporary (less than 30
days) recording and monitoring of brain electrical activity, which is
cleared to market in the United States.
